The American group ABBOTT LABORATORIES will acquire a significant stake in the capital of its fellow national MILLENIUM in order to jointly develop and market medicines against diabetes and obesity. It will initially acquire MILLENIUM shares for a value of USD 50 million then, for the equivalent of USD 200 million during the next two years.